Insider Buying: Senseonics (NYSE:SENS) CFO Buys $31,840.20 in Stock

Senseonics Holdings, Inc. (NYSE:SENS) CFO Frederick Sullivan purchased 5,415 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were purchased at an average price of $5.88 per share, with a total value of $31,840.20. Following the completion of the acquisition, the chief financial officer directly owned 157,028 shares of the company’s stock, valued at approximately $923,324.64. This trade represents a 3.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Senseonics Trading Up 1.2%

Senseonics stock opened at $6.59 on Thursday. Senseonics Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $28.00. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The firm has a market capitalization of $269.25 million, a PE ratio of -50.69 and a beta of 0.79. The business’s 50-day simple moving average is $8.27 and its 200-day simple moving average is $9.76.

Institutional Investors Weigh In On Senseonics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Smith Salley Wealth Management raised its stake in shares of Senseonics by 10.9% in the 3rd quarter. Smith Salley Wealth Management now owns 61,000 shares of the company’s stock valued at $27,000 after buying an additional 6,000 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new position in Senseonics in the first quarter worth about $31,000. IFP Advisors Inc lifted its stake in Senseonics by 120.9% during the first quarter. IFP Advisors Inc now owns 47,500 shares of the company’s stock worth $31,000 after purchasing an additional 26,000 shares during the period. Elite Life Management LLC acquired a new stake in Senseonics during the second quarter valued at approximately $36,000. Finally, HBK Sorce Advisory LLC acquired a new stake in Senseonics during the third quarter valued at approximately $39,000. Institutional investors own 12.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Stifel Nicolaus assumed coverage on Senseonics in a report on Tuesday, October 21st. They set a “hold” rating and a $9.00 price target for the company. Lake Street Capital upgraded shares of Senseonics to a “strong-buy” rating in a research note on Thursday, July 17th. HC Wainwright increased their price target on shares of Senseonics to $18.50 and gave the company a “buy” rating in a report on Thursday, November 6th. TD Cowen dropped their price objective on shares of Senseonics from $25.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, Barclays reaffirmed an “overweight” rating and set a $31.00 price objective (up previously from $1.50) on shares of Senseonics in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $22.70.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.